Arrowhead Pharmaceuticals, Inc. logo

ARWR

Arrowhead Pharmaceuticals, Inc.

$25.84

Earnings Summary

Revenue
$0Mn
Net Profits
$-125.3Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Arrowhead Pharmaceuticals, Inc.’s revenue fell -100% since last year same period to $0Mn in the Q1 2024. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated -100% fall in its revenue since last 3-months.

Net Profits:

Arrowhead Pharmaceuticals, Inc.’s net profit fell -357.42% since last year same period to $-125.3Mn in the Q1 2024. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated 5.69% jump in its net profits since last 3-months.

Net Profit Margins:

Arrowhead Pharmaceuticals, Inc.’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2024. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Arrowhead Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.55
EPS Estimate Current Year
-0.55

Highlights

EPS Estimate Current Quarter:

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.55 - a -243.75% fall from last quarter’s estimates.

EPS Estimate Current Year:

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.55.

Key Ratios

Key ratios of the Arrowhead Pharmaceuticals, Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
-1.02
Return on Assets (ROA)
-0.32
Return on Equity (ROE)
-0.99

Highlights

Earning Per Share (EPS):

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) fell -326.67% since last year same period to -1.02 in the Q1 2024. This indicates that the Arrowhead Pharmaceuticals, Inc. has generated -326.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arrowhead Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.32.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arrowhead Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.99.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-09
-0.16
-1.02
-537.5%